Latest News About Nevanac Eye Drop

Here’s the latest readily available information on Nevanac eye drops (nepafenac):

• What Nevanac is used for: It’s an NSAID eye drop used to reduce pain and inflammation after cataract surgery and, in some indications, to reduce the risk of macular edema in diabetic patients after cataract surgery [EMA: Nevanac EPAR summary].[3]

• Important safety notes: Post-marketing data and regulatory summaries note possible corneal adverse events, including corneal epithelial defects or more serious issues, particularly with prolonged NSAID use or certain risk factors. If signs of corneal problems occur, discontinue use and seek ophthalmic evaluation promptly [EMA: Nevanac EPAR; SMPC and PIL summaries cited in multiple sources].[2][4][5]

• Dosing and duration: For the 1 mg/mL formulation, typical regimens involve multiple instillations per day beginning around the time of cataract surgery, with treatment continuing for a period after surgery. The 3 mg/mL strength can be used in once-daily dosing for prevention of inflammation/pain, with duration varying up to about 60 days for macular edema risk in diabetics. Always follow your surgeon’s or prescriber’s specific instructions. Regulatory documents summarize these dosing patterns and cautions on duration and lens wear during treatment [EMA EPAR; EMA product information; FDA labels].[4][6][3]

• Key cautions and interactions: Do not use if allergic to nepafenac or other NSAIDs. Benzalkonium chloride is an excipient that can affect contact lenses, so avoid lens wear during treatment unless advised otherwise. Patients with prior corneal disease or at risk of corneal epithelial breakdown should use with caution and monitor closely [EMA EMA EPAR; UK SmPC and PIL documents].[5][2][4]

• Availability and regulation by region: Nevanac is prescription-only in Europe and has accompanying EU/UK product information and FDA labeling. Local availability and exact dosing schedules can vary by country and year; check with a local ophthalmologist or pharmacist for the most relevant guidance in your region [EMA EPAR; UK SMPC; FDA labeling].[6][2][3]

Illustration (example of typical use): One drop into the affected eye(s) several times daily around the time of cataract surgery, then tapering as advised by a clinician, with vigilance for any eye surface symptoms—redness, pain, reduced vision, or tearing, which would warrant prompt medical review [EMA EPAR; PIL summaries].[3][5]

If you’d like, I can tailor this to your country (Poland) and provide the most relevant local regulatory references and patient information leaflets. I can also summarize recent regulatory communications or provide a quick checklist for monitoring during Nevanac therapy.

Citations:

• Nevanac uses and dosing/indications: European Medicines Agency EPAR and product information.[4][3]
• Safety/post-marketing corneal risk and cautions: EMA EPAR and PIL resources.[2][5][4]
• UK/SMP guidance and labeling: Medicines.org.uk SMPCs and PILs.[10][2]